Bicara Therapeutics Inc. (BCAX) — 8-K Filings

8-K Filings (9)

• 8-K Filing — May 11, 2026
• Bicara Therapeutics Files 8-K with Q4 2025 Results — Mar 30, 2026 Risk: low
  Bicara Therapeutics Inc. filed an 8-K on March 30, 2026, reporting its financial results for the period ending March 30, 2026. The filing includes Item 2.02 (Re
• 8-K Filing — Dec 8, 2025
• Bicara Therapeutics Files 8-K on Shareholder Matters — Jun 12, 2025 Risk: low
  Bicara Therapeutics Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders as of June 9, 2025. The filing details the
• Bicara Therapeutics Enters Material Definitive Agreement — Jun 6, 2025 Risk: medium
  Bicara Therapeutics Inc. announced on June 2, 2025, that it has entered into a Material Definitive Agreement. The company, incorporated in Delaware, is involved
• Bicara Therapeutics Files 8-K on Financials — Mar 27, 2025 Risk: low
  Bicara Therapeutics Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Bicara Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  On January 13, 2025, Bicara Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Bicara Therapeutics Files 8-K on Financials — Nov 12, 2024 Risk: low
  Bicara Therapeutics Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation
• Bicara Therapeutics Relocates Offices — Sep 16, 2024 Risk: low
  Bicara Therapeutics Inc. filed an 8-K on September 16, 2024, reporting a change in its principal executive offices to 116 Huntington Avenue, Suite 703, Boston,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX